Abstract
In the context of globally increasing antimicrobial resistance, tigecycline appears to be a useful therapeutic option. The need for prolonged courses for complex infections has prompted consideration of its use via outpatient parenteral antibiotic therapy (OPAT) programmes, although clinical outcomes when used in this setting remain unknown. We retrospectively reviewed the patient characteristics and outcomes of 11 patients who received tigecycline, most commonly delivered as 100 mg once daily, via OPAT at three tertiary Australian hospitals. Rates of co-morbidity and prior antibiotic use were high. Patients had a wide range of infections including bone and/or joint (n = 5), intra-abdominal (n = 3), lower respiratory tract (n = 2) and parapharyngeal abscess (n = 1). Mycobacterial species (n = 5) were the most frequent pathogen, and multi-resistant organisms were common (n = 4). The median OPAT duration was 14 days (IQR 6–30). Nausea was encountered in 45 % of cases. At completion of OPAT, 1 patient (9 %) was cured, 2 (18 %) had improved and 8 (73 %) failed therapy. Failure occurred due to either progression or non-response of infection (n = 4), re-admission (n = 3), premature cessation of tigecycline due to nausea (n = 3) or death (n = 1). Whilst OPAT delivery of tigecycline is a therapeutic option, when used as second-line therapy for complex, often multi-resistant infections in patients with multiple comorbidities, high rates of clinical failure, readmissions and adverse effects, especially nausea, should be anticipated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stein GE, Craig WA (2006) Tigecycline: a critical analysis. Clin Infect Dis 43(4):518–524
European Medicines Agency (2011) Summary of Product Characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000644/WC500044508.pdf. Accessed 2 June 2016
Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B (2014) Clinical experience in 52 patients with Tigecycline-containing regimens for salvage treatment of mycobacterium abscessus and mycobacterium chelonae infections. J Antimicrob Chemother 69(7):1945–1953
Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S (2005) Pharmacokinetics of Tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49(1):220–229
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Manning L, Wright C, Ingram PR, Whitmore TJ, Heath CH, Manson I, Page-Sharp M, Salman S, Dyer J, Davis TM (2014) Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability. PLoS One 9(7), e102023
Prasad P, Sun J, Danner RL, Natanson C (2012) Excess deaths associated with Tigecycline after approval based on noninferiority trials. Clin Infect Dis 54(12):1699–1709
De Rosa FG, Corcione S, Di Perri G, Scaglione F (2015) Re-defining tigecycline therapy. New Microbiol 38(2):121–136
MacGowan AP (2008) Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 62(Suppl 1):i11–16
Lauf L, Ozsvar Z, Mitha I, Regoly-Merei J, Embil JM, Cooper A, Sabol MB, Castaing N, Dartois N, Yan J, Dukart G, Maroko R (2014) Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis 78(4):469–480
Griffin AT, Harting JA, Christensen DM (2013) Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diagn Microbiol Infect Dis 77(3):273–277
Cunha BA (2007) Once-daily Tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 19(2):232–233
Baxter Australia Pharmacy Service Product Stability Antibiotics, https://www.baxterprofessional.com.au/lsds/ANZ/external_html/BPS2190_Baxter_Shelf_Life_app_20150618_web/index.html#/antibiotics/tigecycline Accessed 7 April 2016
Lee B, Tam I, Weigel B, Breeze JL, Paulus JK, Nelson J, Allison GM (2015) Comparative outcomes of beta-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches. J Antimicrob Chemother 70(8):2389–2396
Guirao X, Sanchez Garcia M, Bassetti M, Bodmann KF, Dupont H, Montravers P, Heizmann WR, Capparella MR, Simoneau D, Eckmann C (2013) Safety and tolerability of Tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother 68(2):ii37–44
Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM (2005) Effects of age and sex on single-dose pharmacokinetics of Tigecycline in healthy subjects. Antimicrob Agents Chemother 49(4):1656–1659
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Jason Roberts is supported in part by a Career Development Fellowship from the Australian National Health and Medical Research Council of Australia (APP1048652).
Ethical approval
Human research ethics committee approval was obtained from Royal Perth Hospital (14–107).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Conflicts of interest
Dr. Paul Ingram has previously received financial support from Pfizer to attend an educational symposium. Dr. R. Murray has previously received honoraria from Wyeth for speaking at a symposium. Dr. Laurens Manning has attended advisory board meetings and received honoraria from MSD. The remaining authors declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Ingram, P.R., Rawlins, M.D.M., Murray, R.J. et al. Tigecycline use in the outpatient parenteral antibiotic therapy setting. Eur J Clin Microbiol Infect Dis 35, 1673–1677 (2016). https://doi.org/10.1007/s10096-016-2709-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-016-2709-6